The September 2021 issue of Drug Development & Delivery takes a deep dive into injectables that are either currently in development or recently introduced to the market. This year’s report features our VP of Technical Solutions, Michael Denzer, as he highlights Kymanox’s ability to provide end-to-end solutions to accelerate device development and delivery.

Read More

Read Our Recent Blogs

Kymanox Acquires Agilis Consulting Group, A Trusted Human Factors Provider

Kymanox Acquires Agilis Consulting Group, A Trusted Human Factors Provider Integrating the well-respected and trusted Agilis brand and team extends Kymanox’s capabilities in human factors (HF) by adding incredible talent, the ability to conduct HF stu...

Investment Reports Interview with Stephen M. Perry, CEO and Founder of Kymanox

Kymanox CEO and Founder, Stephen M. Perry was interviewed as part of the Investment Reports article, The New Era of Life Sciences 2023, published on 17MAR23, What were the circumstances that brought Kymanox to life and what does your present foo...

Kymanox Acquires EU Based Anteris Medical and Anteris Helvetia

Leveraging the well-respected anteris brand and team, this acquisition extends Kymanox’s capabilities and geographic reach with a strong European presence   Friday, 03 February 2023 Morrisville, North Carolina, USA and Holzkirchen, Germany an...
See More Blogs